X

Drug Profile

RTP 026

Alternative Names: RTP-026

Latest Information Update: 21 Jun 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ResoTher Pharma
Class Anti-inflammatories; Cardiovascular therapies; Peptidomimetics
Mechanism of Action Formyl peptide receptor modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Myocardial infarction

Most Recent Events

10 Jun 2024 Phase-II clinical trials in Myocardial infarction in Denmark (Parenteral) (NCT06465303)
06 Nov 2023 ResoTher Pharma receives EIC grant from European Innovation Council for phase II development of RTP 026 in Myocardial infarction
06 Nov 2023 Phase-I clinical trials in Myocardial infarction (In volunteers) (Parenteral) prior to November, 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com